Table 4 Non-cardiovascular morbidity of participants in the BELFRAIL cohort (n = 567)
| Â | Active pathology* n (%) | Cured pathology n (%) | Unknown$, n (%) |
|---|---|---|---|
Thyroid dysfunction | 51 (9.0) | 23 (4.1) | 1 (0.2) |
   Hypofunction | 47 (8.4) | 5 (0.9) | 2 (0.4) |
   Hyperfunction | 1 (0.2) | 15 (2.7) | 3 (0.5) |
Anaemia | 50 (8.9) | 23 (4.1) | 0 (0) |
Asthma | 27 (4.8) | 7 (1.2) | 5 (0.9) |
COPD | 65 (11.5) | - | 12 (2.1) |
Parkinson's disease | 16 (2.8) | - | 3 (0.5) |
Arthritis | 28 (5.0) | 23 (4.1) | 1 (0.2) |
Osteoarthritis | 324 (58.0) | - | 4 (0.7) |
Osteoporosis | 125 (22.5) | - | 17 (3.1) |
Cancer | 43 (7.6) | 73 (12.9) | 5 (0.9) |
Depression | 74 (13.1) | 32 (5.7) | 8 (1.4) |
Renal insufficiency | 64 (11.4) | 5 (0.9) | 9 (1.6) |
Hip prosthesis£ | 73 (13.0) | - | - |
Knee prosthesis£ | 44 (7.8) | - | - |